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Pulmonary hypertension is a rare disease with a poor prognosis. It was first described in the
late 19th century as a clinical-pathological syndrome characterised by obstruction of the
small pulmonary arteries and right ventricular hypertrophy in patients presenting with
severe dyspnoea and cyanosis. After the development of right heart catheterisation in the
second half of the 20th century, it was found that many diseases could cause pulmonary
hypertension, which is now recognised to be high blood pressure in the arteries that supply
the lungs. In the 1960s, an epidemic of pulmonary hypertension caused by appetite
suppressants initiated a systematic collection of information on pulmonary hypertension,
leading to the first international classification of pulmonary hypertension. Increased
understanding of the pathogenesis of the various forms of pulmonary hypertension has led
to novel treatments and holds promise for the future.
& 2006 Elsevier Ltd. All rights reserved.Introduction
In 1957, Oscar Brenner, a pathologist from Birmingham,
England, wrote a review for this journal titled, The Lungs in
Heart Disease.1 He started the introduction of his review
with the following statement:
The relationship of the lungs to the heart is very close,
and it is not surprising that diseases of the lung mayElsevier Ltd. All rights reserved.
444728; fax: +31 204444382.
. Vonk Noordegraaf).affect the heart and diseases of the heart may affect the
lungs. It is, of course, by way of the pulmonary blood
vessels that this interrelationship is affected.
Although this statement seems obvious to us, it took a
long time to recognise this relationship. From the late 19th
century until the first half of the 20th century, several
clinical-pathological case reports were published about
patients with a distinctive syndrome involving obstructive
lesions in the small pulmonary arteries and right ventricular
hypertrophy.2–11 Right heart catheterisation, developed in
the second half of the 20th century, allowed detection of
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Table 1 Clinical classification of pulmonary hypertension—Venice 2003.
Group 1: Pulmonary arterial hypertension (PAH)
1.1. Idiopathic (IPAH)
1.2. Familial (FPAH)
1.3. Associated with (APAH):
1.3.1. Connective tissue disease
1.3.2. Congenital systemic to pulmonary shunts
1.3.3. Portal hypertension
1.3.4. HIV infection
1.3.5. Drugs and toxins
1.3.6. Other (thyroid disorders, glycogen storage disease, Gaucher’s disease, hereditary haemorrhagic telangiectasia,
haemoglobinopathies, myeloproliferative disorders, splenectomy)
1.4. Associated with significant venous or capillary involvement
1.4.1. Pulmonary veno-occlusive disease (PVOD)
1.4.2. Pulmonary capillary haemangiomatosis (PCH)
1.5. Persistent pulmonary hypertension of the newborn (PPHN)
Group 2: Pulmonary hypertension associated with left heart diseases
2.1. Left-sided atrial or ventricular heart disease
2.2. Left-sided valvular heart disease
Group 3: Pulmonary hypertension associated with lung respiratory diseases and/or hypoxia
3.1. Chronic obstructive pulmonary disease
3.2. Interstitial lung disease
3.3. Sleep disordered breathing
3.4. Alveolar hypoventilation disorders
3.5. Chronic exposure to high altitude
3.6. Developmental abnormalities
Group 4: Pulmonary hypertension due to chronic thrombotic and/or embolic disease
4.1. Thromboembolic obstruction of proximal pulmonary arteries
4.2. Thromboembolic obstruction of distal pulmonary arteries
4.3. Non-thrombotic pulmonary embolism (tumour, parasites, foreign material)
Group 5: Miscellaneous
Sarcoidosis, histiocytosis X, lymphangiomatosis, compression of pulmonary vessels (adenopathy, tumour, fibrosing
mediastinitis)
S.A. van Wolferen et al.390elevated pulmonary artery pressure, thus linking pulmonary
vascular disease to right ventricular hypertrophy. Pulmonary
hypertension was defined as mean pulmonary artery
pressure in excess of 25mmHg at rest, or exceeding
30mmHg with exertion. Classifications of pulmonary hyper-
tension were made, identifying both primary pulmonary
arterial hypertension, later named idiopathic pulmonary
arterial hypertension (IPAH), and also various conditions
associated with pulmonary hypertension12 (Table 1).The first clinical case reports
In 1865 the German physician Klob reported the autopsy
findings of a patient who had developed progressive ankle
oedema, dyspnoea and cyanosis prior to his death at age
59.2 Instead of the cardiac pathology he had expected, Klob
found an impressive narrowing of the finer branches of the
pulmonary artery with localised arteriosclerosis. In 1891,
Romberg, a renowned German physician, described a similar
clinical course in a 24-year-old patient.3 At the autopsy,
other than the abnormalities in the pulmonary vessels,which he called ‘pulmonary vascular sclerosis’, he also
noted massive right ventricular hypertrophy. The Argenti-
nean physician Arrillaga was the first to describe a series of
patients with pulmonary hypertension in 1913, after being
made aware of the condition by his professor Ayerza.5,6 The
combination of cyanosis and death by right heart failure was
named Ayerza’s disease or ‘black heart disease’, due to the
dark skin colour of the severely cyanotic patients. Arrillaga
suggested that the cause of Ayerza’s disease was syphilis
that had spread to the pulmonary arteries. Eventually, in
1935, Brenner would disprove the syphilis theory after
studying 100 cases of pulmonary hypertension at the
Pathology Department of Massachusetts General Hospital.9
However, at that time Brenner could not offer an alternative
explanation for the pathological findings of right ventricular
hypertrophy and pulmonary vascular sclerosis.Diagnosis of pulmonary hypertension
In 1852, Beuser in Leipzig, Germany, was the first to perform
a measurement of the pulmonary artery pressure in a cat,
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professor, Ludwig, had done on the much more accessible
systemic circulation. The first introduction of a catheter into
a human pulmonary artery was performed by Forssmann. In
1929, Forssman inserted a urinary catheter into his own
antecubital vein, and, guided by fluoroscopy, placed it in his
right heart (Fig. 1a).13 Disappointed by the negative
reactions of the medical profession and the lack of
acceptance in cardiology, he eventually became an urologist
and abandoned his experiments. Cournard and Richards
further developed this technique in the 1940s. Forsmann
finally received recognition for his pioneering work in 1956,
when he, together with Cournard and Richards, received the
Nobel Prize for the development of right heart catheterisa-
tion (Fig. 1b).14,15
Non-invasive alternatives to diagnose pulmonary hyper-
tension were sought. Although a simple chest X-ray orFigure 1 (a) Original fluoroscopy image of one of the
experiments by Werner Forssmann. The cathether was inserted
in the left arm and the tip positioned within the heart. (b) Prof.
Dr. Werner Forssmann. His achievements in catheterising the
right heart in 1929 were ignored by his colleagues for many
years. In 1956, he received the Nobel Prize together with
Cournand and Richards.electrocardiogram provides clues as to whether pulmonary
hypertension is present or not,16–20 a breakthrough came
with the development of Doppler echocardiography in the
late 1970s. The blood flow over the tricuspid valves
appeared to predict systolic pulmonary artery pressure,
while the structural information gained using this technique
allowed the effect of hypertension on the right ventricle to
be evaluated. However, despite these advances, right heart
catheterisation is still required to confirm pulmonary
hypertension.21
Once pulmonary hypertension is diagnosed, further
diagnostic work-up to identify possible underlying diseases
is recommended.21 In 1957, pulmonary hypertension was
already divided into 5 classes based on the underlying cause:
chronic bronchitis and emphysema, left to right shunt,
primary pulmonary hypertension, primary pulmonary arter-
iosclerosis and pulmonary embolism.1 At that time, primary
pulmonary arteriosclerosis was regarded as the pathological
counterpart of primary pulmonary hypertension. Advances
in histopathology and understanding of disease pathogenesis
resulted in renewed classifications in 1973 and 1998; these
classifications included several other forms of pulmonary
hypertension. Underlining the impact of the development of
various treatment modalities in recent years, the latest
WHO classification (2003) uses clinical presentation and
management rather than histopathological characteristics
to classify pulmonary hypertension (Table 1).
For example, WHO group 1, pulmonary arterial hyperten-
sion, now includes idiopathic pulmonary arterial hyperten-
sion, a disease with arterial involvement, and pulmonary
veno-occlusive disease (PVOD), a disease with primary
venous involvement. Although both diseases have distinct
clinical, radiological and histological features, similar
molecular pathways are involved in both diseases, hence
similar treatments can be effective in both diseases.
WHO group 1: pulmonary arterial hypertension
Epidemic of pulmonary hypertension caused by
appetite suppressants
In 1968, Gurtner22 was the first to report an epidemic of
pulmonary hypertension cases in Bern, Switzerland. At the
same time, an increased incidence of pulmonary hyperten-
sion was reported in Germany and Austria. Since many of
these patients had used the appetite suppressing drug
aminorex fumarate (Menocil), a causal relationship between
the use of aminorex and the development of pulmonary
hypertension was accepted.23 Later, fenfluramine increased
the incidence of pulmonary hypertension in Europe, while
the combination of fenfluramine and phentermine, which
was popular in the USA, also caused an increase in
pulmonary hypertension cases.24,25 It turned out that the
use of these appetite suppressants increased the risk of
developing pulmonary hypertension tenfold or more. Direct
proof that appetite suppressants cause pulmonary hyperten-
sion was never obtained, as aminorex or other anorexigenic
drugs failed to induce pulmonary hypertension in animal
models.26 The strongest non-epidemiological evidence that
appetite suppressants induce pulmonary hypertension is
that these drugs act as a substrate for the serotonin
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known vasoconstrictor and smooth muscle cell mitogen.27
In response to the epidemic of pulmonary hypertension
caused by appetite-suppressant drugs, the first WHO meet-
ing on pulmonary hypertension was organised in 1973; later,
in 1981, a National Health Registry was started by the US
National Institutes of Health to collect information about
the epidemiology, natural course, and histopathologic and
clinical characteristics of pulmonary arterial hypertension
(PAH). After 6 years of data collection, this registry proved
to be very successful and became a valuable resource for
systematically evaluating treatment for PAH for the centres
involved in the registry.28–30 Although the unanticipated side
effect of appetite suppressants caused harm to many
people, the establishment of the registry in response to
appetite suppressant-induced PAH resulted in a great boost
to the understanding of the pathogenesis and treatment of
many forms of PAH.
One of the major results of global research into the
pathogenesis of PAH was the discovery of the bone
morphogenetic protein receptor (BMPR)-2.31,32 A genetic
mutation in this receptor was found in 50% of patients with
familial pulmonary arterial hypertension and in 26% of
sporadic cases of pulmonary arterial hypertension.33 The
true incidence of defects in the BMPR-2 gene is probably
much higher: recently, exonic BMPR-2 deletions and dupli-
cations were identified that account for a large proportion
of BMPR-2 mutations that have remained undetected until
now.34 Mutations in BMPR-2 result in a genetic predisposition
to develop PAH; however, both in familial PAH and in
sporadic PAH, a second-hit or several other triggers are
required to develop PAH. These triggers include mutations
or polymorphisms in other genes that have been identified
and linked to PAH, such as the serotonin receptor and
transporter, and exogenous factors such as appetite-sup-
pressant drugs.23,35From understanding pathogenesis to developing
treatments for pulmonary arterial hypertension
In pulmonary hypertension, pathologic abnormalities are
present in all three layers of the pulmonary arteries, and
media hypertrophy due to proliferation of smooth muscle
cells is a constant feature of all forms of pulmonary
hypertension.36 Calcium channel blockers have been shown
to inhibit the contraction of pulmonary artery smooth
muscle cells.37 Calcium channel blockers reduce right
ventricular hypertrophy and improve long-term hemody-
namics in PAH, but only in the small subset of patients who
also show an acute hemodynamic response.38,39 A study
found that survival was greatly improved in patients who
showed a long-term response to calcium channel blockers;
however, in patients that failed on long-term calcium
channel blocker therapy, the 5-year survival rate was only
48%.40 Calcium channel blockers are now only recommended
for patients with a positive response during acute vasor-
eactivity testing and who show sustained hemodynamic
improvement.21
A new era in the treatment of PAH began in 1984 when
epoprostenol, a natural prostacyclin, was first used with
remarkable results in a patient with pulmonary hyperten-sion.41 Prostacyclin was discovered as a metabolite of
prostaglandin with potent anti-platelet aggregatory activity
and pulmonary vasodilator activity.42,43 Endothelial cells of
patients with pulmonary hypertension produce decreased
amounts of prostacyclin.44,45 Barst et al.46 showed that
patients treated with prostastacyclin showed improved
exercise capacity, functional status and hemodynamics
compared to control patients receiving conventional treat-
ment. In that same study, a significant difference in survival
after 12 weeks was found: 8 deaths in the control group,
compared to no deaths in the intravenous prostacyclin
group. Since then, no long-term randomised controlled trials
with intravenous prostacyclin for PAH have been conducted.
However, two long-term cohort studies of patients with IPAH
receiving intravenous epoprostenol showed considerable
benefit compared to historical controls. In one 3-year study
of 162 patients with IPAH, survival with epoprostenol was
88% at 1 year, 76% at 2 years and 63% at 3 years compared to
the expected survival of 59% at 1 year, 46% at 2 years and
35% at 3 years.47 In another 5-year study of 178 patients with
IPAH, survival with epoprostenol was 85% at 1 year, 70% at 2
years, 63% at 3 years and 55% at 5 years compared to
expected survival rates of 58% at 1 year, 43% at 2 years, 33%
at 3 years and 28% at 5 years.48 The down side of this drug is
that it requires continuous intravenous administration,
rendering it unsuitable for some patients and unavailable
in some countries. Other, more stable prostacyclin analo-
gues have been synthesised for different forms of adminis-
tration, including oral, inhalatory and subcutaneous
routes.49
Continuing advances in the field of molecular biology has
made targeted therapy possible for treating PAH. Giaid et
al.50 demonstrated that the endothelial cells of patients
with PAH have increased expression of endothelin-1, a small
peptide that is a potent vasoconstrictor and that has
mitogenic properties. Bosentan was the first endothelin
receptor antagonist that showed positive results, as mea-
sured by an improvement in the walking distance during
the 6-min walk test and an improvement in the time to
clinical worsening in placebo-controlled trials; clinical
worsening was defined as death, lung transplantation,
hospitalisation for pulmonary hypertension, a lack of
clinical improvement or worsening leading to discontinua-
tion of treatment, a need for epoprostenol therapy or
atrial septostomy.51,52 Sitaxsentan, an endothelin receptor
antagonist with more selective properties, showed similar
results.53,54 Other selective endothelin receptor antagonists
are currently under investigation. Long-term survival
rates of 96% at 1 year and 89% at 2 years have been
reported for bosentan therapy as a first-line therapy, while
additional or other therapies are used in case of clinical
deterioration.55
Sildenafil is a vasodilator that was first used to ameliorate
the effects of inhaled nitric oxide withdrawal.56 Sildenafil
blocks the enzyme phosphodiesterase 5, inhibiting the
degradation of cyclic guanosine monophosphate (cGMP), a
second messenger in the nitric oxide pathway that induces
vascular relaxation. Reports of the beneficial effects of
sildenafil in patients with pulmonary hypertension led to
randomised clinical trials, which showed that treatment
resulted in an improvement in exercise capacity, WHO
functional class and mean pulmonary artery pressure.57,58
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In the histopathological diagnosis of pulmonary hypertension
plexiform lesions were first considered a distinct feature of
IPAH and were therefore a focus of investigation into the
origin of cell types involved in the pathogenesis of
pulmonary hypertension (Fig. 2). Early histopathological
descriptions of obstructions in the small pulmonary arteries
supplied evidence of the nature of the cells involved in
pulmonary hypertension: in 1946, Gilmour and Evans59
described intimal lesions containing phenotypically altered
endothelial cells, and predicted that the lesions were
caused by proliferating endothelial cells. Some believed
that these plexiform lesions consisted of smooth muscle
cells that had transformed into myofibroblasts,60,61 but it
was later shown that in IPAH, plexiform lesions consisted of
monoclonal proliferation of endothelial cells.62 More recent
studies have broadened the view of vascular plasticity,
showing that phenotypic modulation of the media partici-
pates in vascular remodelling.63 Plexiform lesions are
typically found in the idiopathic form of pulmonary
hypertension, but have also been observed in other types
of PAH in WHO group 1.64Figure 2 Plexogenic pulmonary arteriopathy featuring a
plexiform lesion (upper-left centre) consisting of a number of
slit-like vessels lined by cobblestone-like endothelium and
surrounded by loose-textured fibrous tissue. The lesion is
flanked by distended vessels, the so-called vein-like branches,
which are presumed to represent widely distended branches of
the feeding axial artery. At the bottom of the photo there is an
axial artery showing prominent medial hyperthrophy. Some
alveolar iron-laden macrophages are in the upper right corner
(haematoxylin and eosin stain).WHO group 2: pulmonary hypertension
associated with left heart disease
Before the 1950s, mitral stenosis due to rheumatic fever was
a common cause of pulmonary hypertension. However,
venous congestion due to any cause may result in the
characteristic histopathological features of congestive heart
disease: arterialisation of the veins due to increased venous
pressure, signs of congestion such as dilated and tortuous
capillaries, alveoli filled with proteinaceous fluid and
haemosiderin-laden macrophages, oedematous inter-lobular
septa and distended lymphatics (Fig. 3). Arterial and venous
adventitial fibrosis are considered characteristic and may be
striking.65 Importantly, the pulmonary artery pressure
generally rises to a greater extent than the venous pressure,
causing arterial changes similar to those observed in
pulmonary arterial hypertension.66 Many of the vascular
changes are reversible when the underlying cause is
treated.67 However, pulmonary hypertension after an acute
myocardial infarction has a poor prognosis.68 The treatment
of this type of pulmonary hypertension is focused on the
underlying left heart disease. Currently, treatment specific
for this type of pulmonary hypertension is lacking.Figure 3 Congestive arteriopathy featuring an axial artery
(centre) with prominent medial hypertrophy, marked adventi-
tial fibrosis and some intimal fibrosis. Some of the alveolar
septae are engorged and widened. The artery in the upper left
quadrant shows multiple lumina in one cross-section, represent-
ing an organised and re-canalised thrombus (elastic van Gieson
stain). Note the smooth muscle hyperplasia of the bronchiole in
this asthmatic patient in the lower right quadrant of the photo.
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associated with lung respiratory diseases and/
or hypoxia
An important discovery was the concept of hypoxic
pulmonary vasoconstriction, first measured in a cat by Von
Euler and Liljestrand69 in 1946, and a year later repeated in
humans by Motley et al.70 in the Cournand–Richards
laboratory (Fig. 4).
Hypoxia at high altitude had long been suspected to cause
death in cattle. However, it took several years before the
adverse effects of chronic hypoxic vasoconstriction on
remodelling of the pulmonary arterioles were recognised.
In 1956, Peirson and Jensen71 concluded that atmospheric
hypoxia causes increased resistance in the pulmonary
circulation and failure of the right ventricle. In that same
year, Canepa et al.72 demonstrated that humans living at
high altitude have a modest increase in mean pulmonary
artery pressure. He attributed the increase in pulmonary
artery pressure to a combination of polycythemia, increased
blood volume, high cardiac output and abnormal ventila-
tion, rather than hypoxia. In 1960, the pathologists
Alexander and Jensen, the cardiologists Grover and Reeves,
and the physiologist Will identified the linear relationship
between the severity of right ventricular hypertrophy and
mean pulmonary artery pressure in cattle at high alti-
tudes.73 Furthermore, they found that 100% oxygen reduced
the mean pulmonary artery pressure in part, but not
completely, indicating that a fixed change in the pulmonary
vascular resistance had occurred. Indeed, the cardiologist
Penaloza, the pathologist Arias-Stella, and their team at the
High Altitude Research Institute in Peru presented a report
at the 1962 Aspen Conference that sustained hypoxia in
humans could induce anatomic narrowing of the pulmonary
arterioles, and that this process was distinct from acute
hypoxic vasoconstriction.74 Characteristic histological fea-
tures of hypoxic pulmonary vasculopathy are medial
hypertrophy of the small pulmonary arteries, muscularisa-
tion of the pulmonary arterioles and, to a lesser extent, the
pulmonary veins and venules. In addition, longitudinal
bundles of smooth muscle cells in the intima may devel-Figure 4 First recording of hypoxic pulmonary vasoconstric-
tion in a cat during mechanical ventilation. 6.2% of CO2 in pure
oxygen caused a moderate rise in pulmonary arterial pressure,
and hypoxaemia (10.5% O2) caused a large rise in pulmonary
arterial pressure. Acidosis achieved by 19% CO2 only caused an
increase in left atrial pressure.op,75,76 supporting the concept of vascular remodelling
through endothelial transdifferentiation.63 An important
mechanism in the pathogenesis includes an altered function
of potassium-channels in hypoxia, causing decreased apop-
tosis and increased constriction and proliferation of smooth
muscle cells.77,78
In Brenner’s 1957 review, The Lungs in Heart Disease,
chronic bronchitis and emphysema were already recognised
as distinct causes of pulmonary hypertension.1 Today, it is
understood that hypoxic pulmonary hypertension may
complicate various other diseases such as asthma, bronch-
iectasis, cystic fibrosis and sleep apnoea syndrome. Although
only a small percentage of patients with respiratory diseases
develop pulmonary hypertension, this still constitutes a
large number of patients.79 In chronic obstructive pulmon-
ary disease (COPD), mild pulmonary hypertension develops
when alveolar hypoxia is present, and treatment is focussed
on supplemental oxygen to relieve hypoxic pulmonary
vasocontriction.80,81 In addition to hypoxia-induced vaso-
constriction, progressive pulmonary vascular remodelling
and loss of the vascular bed can also contribute to increased
pulmonary vascular resistance and to advanced pulmonary
hypertension in some patients. New treatments are sought
for this group of patients.82
WHO group 4: pulmonary hypertension due to
chronic thrombotic and/or embolic disease
In 1953, Owen et al.83 were the first to suggest that
pulmonary hypertension could be caused by recurrent silent
pulmonary embolisms. Pulmonary hypertension associated
with pulmonary embolism was found in 0.1–0.4% of autopsy
cases,84 and prospective studies found that pulmonary
hypertension occurred in 4% of patients after a pulmonary
embolism.85 Virchow’s triad, defined in 1856 and comprising
endothelial damage, altered blood flow and altered blood
composition, is still considered to underlie most cases of
thromboembolic vasculopathy. However, the mechanisms
leading to the development of chronic pulmonary hyperten-
sion after pulmonary embolism are still not entirely clear.
After the first pulmonary endarterectomy, performed at the
University of California at San Diego in 1971, Moser and
Braunwald noted that the pulmonary vascular bed distal to
the thrombotic occlusion was relatively normal, but the non-
obstructed vessels showed lesions resembling IPAH.86 They
suggested that although a pulmonary embolism may be the
initiating event, other mechanisms such as shear stress in
the non-obstructed areas induced small vessel disease and
pulmonary hypertension.
Surgical removal of the thromboembolic obstruction in
the pulmonary arteries is the preferred treatment of chronic
thromboembolic pulmonary hypertension.87 In cases in
which pulmonary endarterectomy is not possible, medical
therapy, similar to that used to treat PAH might be
effective.88–95 These are currently under investigation in
randomised controlled trials.
Monitoring therapy
The development of treatment options led to questions
about how to best monitor treatment efficacy. Because the
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tance are elevated in pulmonary hypertension, initial
studies focussed on measuring hemodynamic changes. Later
trials chose the 6-min walk test, a test of submaximal
exercise capacity, as a surrogate measure of right ventri-
cular performance. Authors of reviews discussing clinical
trial end-points expressed the need for simple and accurate
end-points that would better reflect treatment results.96,97
In 1987, it was suggested by Johnson and Rubin98 that newer
imaging techniques might play an important role in non-
invasively monitoring PAH. Recent technical developments
in CT imaging and MRI make it possible to quantify
abnormalities in the pulmonary vascular bed and the right
ventricle.99 A promising new option for monitoring treat-
ment is measuring plasma brain natriuretic peptide levels.
Known as a marker of left heart failure, elevated levels of
this peptide were found in patients with PAH and appear to
be related to right ventricular function and prognosis.100–102From the past to the future
In the past 100 years, incredible progress in the diagnosis
and management of pulmonary hypertension has been
made: we have come from recognising it as a clinical
syndrome and identifying its histopathological characteris-
tics to measuring arterial pulmonary pressure and develop-
ing several treatment modalities. These advances have
improved the outlook of patients diagnosed with pulmonary
hypertension over the last several decades. Early diagnosis
resulting in early initiation of treatment might further
improve patient outcomes. Effective screening tools are still
being sought to help detect pulmonary hypertension.103–106
This is of increasing importance, as the number of patients
who suffer from hypoxic pulmonary hypertension secondary
to respiratory diseases like COPD is likely to rise, and
because hypoxic and chronic thromboembolic pulmonary
hypertension may have been under-diagnosed in the past.
Much work is being done to develop clinical trials to
evaluate treatment in these patients. As more therapies
for pulmonary arterial hypertension are becoming available,
identifying those patients who will benefit most from
different combinations of therapies is an important task
for the future.
Several classes of drugs targeting pulmonary vascular
remodelling have shown promising results in experimental
models of pulmonary hypertension. For example, blocking
the epidermal growth factor receptor results in apoptosis of
pulmonary vascular smooth muscle cells and improves the
survival of rats with monocrotaline-induced pulmonary
hypertension.107 Similarly, blocking platelet-derived growth
factor signalling with imatinib, a tyrosine kinase inhibitor,
reversed pulmonary hypertension in monocrotaline-treated
rats108 and in a single case report.109 Other substances that
have been tested in monocrotaline rat models of pulmonary
hypertension include rho kinase inhibitors110 and serotonin
transporter inhibitors.111 These drugs have been developed
for other indications, and it is important to establish their
long-term efficacy and safety for treatment of pulmonary
hypertension in randomised controlled clinical trials.
Finally, the use of gene therapy to induce apoptosis of
pulmonary vascular cells112 and the use of bone marrow-derived endothelial progenitor cells to replace and regen-
erate damaged endothelium in monocrotaline rat models
may lead to novel therapeutic options in patients with
pulmonary hypertension.113
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